<html>
<head><meta charset="utf-8" /></head>
<body>
    <div>                        <script type="text/javascript">window.PlotlyConfig = {MathJaxConfig: 'local'};</script>
        <script charset="utf-8" src="https://cdn.plot.ly/plotly-3.0.1.min.js"></script>                <div id="9c279046-25b6-4156-83e5-7fed960b252f" class="plotly-graph-div" style="height:800px; width:100%;"></div>            <script type="text/javascript">                window.PLOTLYENV=window.PLOTLYENV || {};                                if (document.getElementById("9c279046-25b6-4156-83e5-7fed960b252f")) {                    Plotly.newPlot(                        "9c279046-25b6-4156-83e5-7fed960b252f",                        [{"hoverinfo":"text","lat":{"dtype":"f8","bdata":"dbD+z2FSRECcvwmFCBA+QHOAYI4eQ0pAGoaPiCmtQEAaho+IKa1AQBqGj4gprUBAHY8ZqIxfQUBvKlJhbAlBQI5AvK5fFEFAX+\u002f+eK8GQUBf7\u002f54rwZBQF\u002fv\u002fnivBkFAX+\u002f+eK8GQUBf7\u002f54rwZBQBtkkpGzuDlAKLhYUYNROkAgRgiPNsY5QCBGCI82xjlAN091yM3sREA3T3XIzexEQIz4Tsx6xURAGcqJdhXOREBhGoaPiMFEQL8rgv+t0ERA9kArMGTJREDMtP0rK6VDQMy0\u002fSsrpUNA4PPDCOEtRUDg88MI4S1FQO2ZJQFqhklAVIzzN6G0RkAhzVg0ndlFQK62Yn\u002fZEUFAX+\u002f+eK8GQUAdWmQ7399AQDdPdcjN7ERAxjNo6J\u002fUREDjqrLviiBDQOZ0WUxsKkVAJSNnYU97RUDwoq8gzaBEQKyL22gAw0ZA4V0u4jsVQkA10lJ5O8I\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\u002fC9Sj0Q0AdWmQ7399AQFyPwvUo9ENALudSXFUOSECe6pCb4cZCQJ7qkJvhxkJADMhe7\u002f5cQkCe0sH6P0c2QFyPwvUo9ENAx9eeWRKQPUBY4gFlUy47QNWytb5I4EtACTiEKjU\u002fRkAuHAjJAjJGQIfcDDfgL0pAoGzKFd4dN0BihPBo4zg\u002fQCtNSkG3DzpApvJ2hNN6OEDBxYoaTAdCQAzIXu\u002f+YEFABmSvd3\u002fAQEDEd2LWi1VCQCtNSkG3F0JAYoTwaOM4P0A1JO6x9Ak5QD81XrpJDEJAXI\u002fC9Sj0Q0Dk2lAxzt9GQOTaUDHO30ZAmpmZmZkZSkCTxmgdVZU+QIwVNZiGfUNA3rBtUWbDPUAaFw6EZLlAQPzjvWplFkJAPq4NFeOwRkAZraOqCa5EQA=="},"legendgroup":"all","lon":{"dtype":"f8","bdata":"kSdJ10zuNkDVyoRf6j8\u002fQMMN+Pww0ipABmSvd3\u002fyW8AGZK93f\u002fJbwAZkr3d\u002f8lvA6s9+pIgSV8AaqIx\u002fn5ldwEPFOH8ToF3AHaz\u002fc5iPXcAdrP9zmI9dwB2s\u002f3OYj13AHaz\u002fc5iPXcAdrP9zmI9dwKG5TiMtEVTAzse1oWIGVMDGounsZAxUwMai6exkDFTA8rBQa5rpVcDysFBrmulVwAvSjEXT61XAwf9WsmPpVcAyrOKNzP1VwMIv9fOm9lXAgIKLFTXyVcAMPPceLidTwAw89x4uJ1PAC9KMRdPDUcAL0oxF08NRwEErMGR1hVzAvyuC\u002f63sUsDKVMGopNpTwE0tW+uLfl3AHaz\u002fc5iPXcAi4BCq1BhVwPKwUGua6VXAgNQmTu7hVsBYkGYsmnBVwLByaJHtwlTAODKP\u002fMFqVcBZi08BMPxXwJrOTgZHq17AJ2vUQzSyVcA+XHLcKZ9awMSUSKKXn1jAQdR9AFLfV8BvnuqQm1NTwIczv5oD+lXAesISDyijUsCdaFch5YVSwCibcoV3gVLA1NSytb5SUsCBCdy6m21SwHWw\u002fs9hgFLAxTh\u002fEwppUsD52jNLAgQmQPnaM0sCBCZA+dozSwIEJkCBsilXeDcVQM3MzMzMjBVA9zsUBfqkF0DECOHRxjERQMQI4dHGsRJARbsKKT\u002fpFUBMGqN1VJUbQE5\u002f9iNFRBpA9zsUBfqkFkCVfVcE\u002fzsXQEW7Cik\u002faRdAtOVciqvqEUDMf0i\u002ffV0UQL+CNGPRyF9AApoIG56+X0ACmggbnr5fQAVpxqLpTBNAsHJoke3CVMDt0\u002fGYgWxUwCdr1EM0slXAjGfQ0D\u002fXV8CmCkYldTJTQMFz7+GSw1PAU9DtJY0hKUBtVn2utlBdwHhi1ouhnlxAJJwWvOhrJEACmggbnr5fQGfyzTY3uFPAxebj2lBdXkAL0oxF08NRwAvSjEXTw1HAJJwWvOhrJEBT0O0ljSEpQFPQ7SWNISlAZmt9kdDGJEBn7bYLzQUpQDihEAGHuFpAhCo1e6AzWMClZg+0AmMTQKVmD7QCYxNAXb9gN2wZXUAi4BCq1BhVwF2\u002fYDdsGV1ARFGgT+TJ+r8M6lvmdF1TwAzqW+Z0XVPAA7LXuz+IU8AMPPceLotcQF2\u002fYDdsGV1AgXhdv2CjWkDl7QinBS8\u002fQOZciqvKzkJAPQrXo3CtJkAaNPRPcDEeQB5QNuUKjxNAAAAAAABQXEDF5uPaUF1eQKG+ZU6X011AgSGrWz2FXUAPuRluwPVZQPN2hNOCaVxAHsTOFDrJXUCyutVz0j9dQEjhehSuR11Axebj2lBdXkAVb2Qe+a1ZQAZkr3d\u002fmFxAXb9gN2wZXUClZg+0AmMTQKVmD7QCYxNAPKBsyhXevT\u002fCNAwfEZFcQDVG66hqRlPAjGfQ0D\u002fXV8AipkQSvQRcwNsWZTbIyFzAj+TyH9JPIkAFi8OZX80AQA=="},"marker":{"color":{"dtype":"i1","bdata":"BzElGxsbGxsbGxsbGxsbGxsbGxsbGxsbGxsbGxsbGxsRERERERERERERERERERERAQEBAQEBARwcHAAAAAAAAAAAAAAAAAAoKCgkJiYmJgYjCAwVHgonFCEhHR0dHSwLDgICLh8aIBYWFisFLykDMAQNExMqKioqKioqKioqGS0tEBcYCQ8PEiI="},"colorscale":[[0.0,"#440154"],[0.1111111111111111,"#482878"],[0.2222222222222222,"#3e4989"],[0.3333333333333333,"#31688e"],[0.4444444444444444,"#26828e"],[0.5555555555555556,"#1f9e89"],[0.6666666666666666,"#35b779"],[0.7777777777777778,"#6ece58"],[0.8888888888888888,"#b5de2b"],[1.0,"#fde725"]],"opacity":0.7,"showscale":false,"size":8},"mode":"markers","name":"All Locations","showlegend":false,"text":["\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT02331966\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e 1st Department of Internal Medicine AHEPA University Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Thessaloniki, , Greece\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06777966\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Nebulized Versus Intravenous Tranexamic Acid on Surgical Field Quality in Patients Undergoing Endoscopic Sinus Surgeries\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Faculty of Medicine, Cairo University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Cairo, , Egypt\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE4\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05821166\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Potential of Moderate Whole Body Hyperthermia to Enhance Response\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Klinik f\u00fcr Radioonkologie und Strahlentherapie\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Berlin, , Germany\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Banner Gateway Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Gilbert, Arizona, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Banner Gateway Medical Pavilion\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Gilbert, Arizona, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Banner MD Anderson Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Gilbert, Arizona, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e University of Arkansas for Medical Sciences - Winthrop P. Rockefeller Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Little Rock, Arkansas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Beverly Hills Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Beverly Hills, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Clinical Research Advisors\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Encino, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Clinical Research Advisors\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaD\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cedars Sinai Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Clinical Research Advisors\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Coral Gables, Florida, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Sylvester Comprehensive Cancer Center- Deerfield Beach\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Deerfield Beach, Florida, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Sylvester Comprehensive Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Miami, Florida, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UHealth Tower\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Miami, Florida, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UChicago Medicine - River East\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Chicago, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e University of Chicago Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Chicago, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UChicago Medicine at Ingalls - Flossmoor\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Flossmoor, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UChicago Medicine Ingalls Memorial\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Harvey, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e University of Chicago Comprehensive Cancer Center at Silver Cross Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e New Lenox, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The University of Chicago Medicine Center for Advanced Care Orland Park\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Orland Park, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UChicago Medicine at Ingalls - Tinley Park\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Tinley Park, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e OIDS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Baltimore, Maryland, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Also Imaging Facility)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Baltimore, Maryland, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Massachusetts General Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Boston, Massachusetts, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Beth Israel Deaconess Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Boston, Massachusetts, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Arthur J.E. Child Comprehensive Cancer Centre\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Calgary, Alberta, Canada\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The Ottawa Hospital - General Campus\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Ottawa, Ontario, Canada\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Princess Margaret Cancer Centre\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Toronto, Ontario, Canada\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e City of Hope\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Duarte, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Valkyrie Clinical Trials\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Winship Cancer Institute - Emory University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Atlanta, Georgia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The University of Chicago Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Chicago, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e University of Iowa\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Iowa City, Iowa, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Norton Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Louisville, Kentucky, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Henry Ford Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Detroit, Michigan, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e START Midwest\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Grand Rapids, Michigan, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Nebraska Cancer Specialists\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Omaha, Nebraska, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Providence Portland Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Portland, Oregon, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Vanderbilt University School of Medicine\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Nashville, Tennessee, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Renovatio Clinical - El Paso\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e El Paso, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e NEXT Oncology\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e San Antonio, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e COMPLETED\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Renovatio Clinical\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e The Woodlands, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Virginia Cancer Specialists\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Fairfax, Virginia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Froedtert Hospital and the Medical College of Wisconsin\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Milwaukee, Wisconsin, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00579566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Basking Ridge, New Jersey, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00579566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Memorial Sloan Kettering Monmouth (Consent and Followup)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Middletown, New Jersey, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00579566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Memorial Sloan Kettering Bergen (Consent and Follow up)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Montvale, New Jersey, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00579566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Memorial Sloan Kettering Commack (Consent and Follow-Up)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Commack, New York, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00579566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Memorial Sloan Kettering Westchester (Consent and Followup)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Harrison, New York, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00579566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Memorial Sloan Kettering Cancer Center (All Protocol Activities)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e New York, New York, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00579566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Memorial Sloan Kettering Nassau (Consent and Followup)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Rockville Centre, New York, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05375266\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Immune Biomarker Study for Head and Neck Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e ENT - Head and Neck Surgery Department\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Erlangen, Bavaria, Germany\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05375266\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Immune Biomarker Study for Head and Neck Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Maxillo-Facial-Surgery Department\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Erlangen, Bavaria, Germany\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05375266\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Immune Biomarker Study for Head and Neck Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Radiation Oncology Department\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Erlangen, Bavaria, Germany\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Jeroen Bosch Ziekenhuis\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e 's-Hertogenbosch, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Meander Medisch Centrum\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Amersfoort, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Ziekenhuis Rijnstate\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Arnhem, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e HagaZiekenhuis\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Den Haag, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Pathologie laboratorium voor Dordrecht\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Dordrecht, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Stichting laboratoria voor pathologische anatomie en medische microbiologie\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Eindhoven, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Laboratorium voor pathologie Oost-Nederland\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Enschede, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Martini Ziekenhuis\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Groningen, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Elkerliek Ziekenhuis\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Helmond, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Laboratorium Volksgezondheid Friesland\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Leeuwarden, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Canisius Wilhelmina Ziekenhuis\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Nijmegen, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Medisch Centrum Rijnmond Zuid\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Rotterdam, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00141466\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Implementation of a New Strategy to Identify HNPCC Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e St. Elisabeth Ziekenhuis\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Tilburg, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06126666\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Seoul National University Bundang Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Seongnam, Seoul, Korea, Republic of\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06126666\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Sevrance Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Seoul, South Korea, Korea, Republic of\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06126666\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Seoul National University Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Seoul, , Korea, Republic of\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05805566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Retrospective and Prospective Cohort of Patients Entering the Multidisciplinary Management of Post-Covid Syndromes\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Department of Acute Pneumology and Thoracic Oncology, H\u00f4pital Lyon Sud, Hospices Civils de Lyon\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Pierre-B\u00e9nite, , France\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06046066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Phase 1 Study of NM6603 in Advanced Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Karmanos Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Detroit, Michigan, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06046066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Phase 1 Study of NM6603 in Advanced Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cleveland Clinic Taussig Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Cleveland, Ohio, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06046066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Phase 1 Study of NM6603 in Advanced Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Tennessee Oncology, PLLC\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Nashville, Tennessee, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06046066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Phase 1 Study of NM6603 in Advanced Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e MD Anderson Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Houston, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT01901666\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Postgraduate Institute of Medical Education and Research\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Chandigarh, UT, India\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE4\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05743426\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e University of North Carolina at Chapel Hill, Department of Radiation Oncology\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Chapel Hill, North Carolina, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT02886026\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Urological department, Frederiksberg Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Copenhagen, , Denmark\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT03598426\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Loma Linda University Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Loma Linda, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE3\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04626726\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e No.2 Hospital of Hebei Medical University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Shijiazhuang, Hebei, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e EARLY_PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05483166\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Engaging Parents in Neuropsychological Rehabilitation for Childhood Cancer Survivors: The ImPACT Program - A Pilot Study\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Aarhus University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Aarhus, , Denmark\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT03449966\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Comparison of Ability of pCLE and WLE for Diagnosis and Cancer Tissue Acquisition in Advanced Gastric Cancer After Chemotherapy Status\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Yonsei university of medical center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Seoul, , Korea, Republic of\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06074666\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Roswell Park Comprehensive Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Buffalo, New York, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04517266\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Ruijin Hospital, Shanghai jiaotong univestigy school of medicine\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Shanghai, Shanghai, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05706766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Dana Farber Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Boston, Massachusetts, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05706766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Dana-Farber Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Boston, Massachusetts, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05376566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Aarhus, , Denmark\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05376566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Department of Haematology, Copenhagen University Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Copenhagen, , Denmark\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05376566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Copenhagen, , Denmark\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05376566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Department of Paediatrics and Adolescent Medicine, Odense University Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Odense, , Denmark\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06588166\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Microbiome Testing for the Screening of Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Fondazione Policlinico Agostino Gemelli, IRCCS\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Roma, , Italy\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT03556566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Open Label Immunotherapy Trial for Ovarian Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Immunitor LLC\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Ulaanbaatar, , Mongolia\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT03769766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UT Southwestern Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Dallas, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE3\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00930566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Extracorporal Photopheresis Pilot Study\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Centre de Sant\u00e9 - Etablissement Fran\u00e7ais du Sang (EFS)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Lyon, , France\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e ACTIVE_NOT_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00930566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Extracorporal Photopheresis Pilot Study\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e H\u00f4pital Edouard Herriot, Service d'H\u00e9matologie\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Lyon, , France\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06733766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Ultrasound-guided Thermal Ablation for Recurrent Thyroid Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Chinese PLA General Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Beijing, Beijing, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05493566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Emory University\u002fWinship Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Atlanta, Georgia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e EARLY_PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05074966\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cancer Hospital & Institute, Chinese Academy of Medical Sciences\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Beijing, , China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE3\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05552066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Anticipated Personalization of the Management in Day Hospital Unit Based on a Collection of the PROs Via a Digital Tool\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Centre de lutte contre le cancer Eug\u00e8ne Marquis\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Rennes, , France\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04643366\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Virginia Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Richmond, Virginia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04643366\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Virginia Commonwealth University Massey Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Richmond, Virginia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04643366\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e VCU Community Memorial Healthcenter\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e South Hill, Virginia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06581666\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Current Awareness, Perspective and Knowledge on Social Egg Freezing\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Pui Wah Jacqueline Chung\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Hong Kong, , Hong Kong\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT01650766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e 307 Hospital of PLA\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Beijing, Beijing, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06766266\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The First Affiliated Hospital of Chongqing Medica University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e ChongQing, , China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06350526\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Radiological Characterization of Pulmonary Involvement in Patients With Hematological Diseases\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Assiut University Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Asy\u016b\u0163, , Egypt\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00964626\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Russian Academy of Medical Sciences Cancer Research Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Moscow, , Russian Federation\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06774326\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e IRCCS Azienda Ospedaliero-Universitaria di Bologna\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Bologna, , Italy\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT01613066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Azienda Ospedaliera S Croce e Carle\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Cuneo, , Italy\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT03646266\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Partial Neuromuscular Blockade for Lung Protective Mechanical Ventilation\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e VUmc\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Amsterdam, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE4\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04417166\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Pembrolizumab and Radiotherapy for Patients With NK\u002fT Cell Lymphoma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Sun Yat-sen University Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Guangzhou, , China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04417166\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Pembrolizumab and Radiotherapy for Patients With NK\u002fT Cell Lymphoma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Shanghai Rui-Jin Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Shanghai, , China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Fujian Cancer Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Fuzhou, Fujian, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The First Affiliated Hospital of Xiamen University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Xiamen, Fujian, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Lanzhou Military Region General Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Lanzhou, Gansu, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The First Affiliated Hospital of Zhengzhou University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Zhengzhou, Henan, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Huai'an Second People's Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Huaian, Jiangsu, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Qianfoshan Hospital of Shandong Province\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Jinan, Shandong, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Taian City Central Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Taian, Shandong, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Fudan University Shanghai Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Shanghai, Shanghai, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Yunnan Cancer Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Kunming, Yunnan, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Anyang Cancer Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Anyang, , China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05009966\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Beijing Cancer Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Beijing, Beijing, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06643026\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Sensory Evaluation of Taste and Smell in Oncology\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e H\u00f4pital Edouard Herriot\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Lyon, , France\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06643026\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Sensory Evaluation of Taste and Smell in Oncology\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e H\u00f4pital Croix Rousse\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Lyon, , France\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e ACTIVE_NOT_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04153526\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e LUCID - LUng Cancer CIrculating Tumour Dna Study\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cambridge Cancer Trials Centre\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Cambridge, Cambridgeshire, United Kingdom\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04909866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B\u002fC Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Wuhan Union Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Wuhan, Hubei, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2, PHASE3\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04969926\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Natural History Study of Parathyroid Disorders\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e National Institutes of Health Clinical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Bethesda, Maryland, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT03425526\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e M D Anderson Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Houston, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04032626\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e St. Joseph's Hospital and Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Phoenix, Arizona, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04032626\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cleveland Clinic Lou Ruvo Center for Brain health\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Las Vegas, Nevada, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04315766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Optimised Lung Cancer Screening to Prevent Cardiovascular and Pulmonary Diseases Coupled With Primary Prevention\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Istituto Clinico Humanitas\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Rozzano, Milano, Italy\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e Not specified\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05726266\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Effect and Safety of Listening to Music for Chronic Pain Relief\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Hospital Universitari de Bellvitge\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e L'Hospitalet De Llobregat, Barcelona, Spain\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e NA\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e"],"visible":true,"type":"scattermapbox"},{"hoverinfo":"text","lat":{"dtype":"f8","bdata":"rrZif9kRQUBf7\u002f54rwZBQB1aZDvf30BAN091yM3sREDGM2jon9REQOOqsu+KIENA5nRZTGwqRUAlI2dhT3tFQPCiryDNoERArIvbaADDRkDhXS7iOxVCQDXSUnk7wj9AW5TZIJNsPUBVGFsIcig+QE6c3O9QbENAPujZrPqERUBq2VpfJLhCQJzEILByyEJAnMQgsHLIQkDmdFlMbCpFQA4tsp3vv0RA4V0u4jsVQkDesG1RZsM9QNMwfERMBUNA5NpQMc7fRkDk2lAxzt9GQB1aZDvf30BAx9eeWRKQPUAuHAjJAjJGQFyPwvUo9ENA3rBtUWbDPUA="},"legendgroup":"phase1","lon":{"dtype":"f8","bdata":"TS1b64t+XcAdrP9zmI9dwCLgEKrUGFXA8rBQa5rpVcCA1CZO7uFWwFiQZiyacFXAsHJoke3CVMA4Mo\u002f8wWpVwFmLTwEw\u002fFfAms5OBkerXsAna9RDNLJVwD5cctwpn1rAxJRIopefWMBB1H0AUt9XwG+e6pCbU1PAhzO\u002fmgP6VcC\u002fgjRj0chfQAKaCBuevl9AApoIG56+X0CwcmiR7cJUwO3T8ZiBbFTAJ2vUQzSyVcCMZ9DQP9dXwHhi1ouhnlxApWYPtAJjE0ClZg+0AmMTQCLgEKrUGFXAgXhdv2CjWkAaNPRPcDEeQF2\u002fYDdsGV1AjGfQ0D\u002fXV8A="},"marker":{"color":{"dtype":"i1","bdata":"AwMDAwMDAwMDAwMDAwMDAwgICAcHBwcEAAAGCQEFAg=="},"colorscale":[[0.0,"#440154"],[0.1111111111111111,"#482878"],[0.2222222222222222,"#3e4989"],[0.3333333333333333,"#31688e"],[0.4444444444444444,"#26828e"],[0.5555555555555556,"#1f9e89"],[0.6666666666666666,"#35b779"],[0.7777777777777778,"#6ece58"],[0.8888888888888888,"#b5de2b"],[1.0,"#fde725"]],"opacity":0.7,"showscale":false,"size":8},"mode":"markers","name":"Phase 1 Locations","showlegend":false,"text":["\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e City of Hope\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Duarte, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Valkyrie Clinical Trials\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Winship Cancer Institute - Emory University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Atlanta, Georgia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The University of Chicago Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Chicago, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e University of Iowa\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Iowa City, Iowa, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Norton Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Louisville, Kentucky, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Henry Ford Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Detroit, Michigan, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e START Midwest\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Grand Rapids, Michigan, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Nebraska Cancer Specialists\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Omaha, Nebraska, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Providence Portland Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Portland, Oregon, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Vanderbilt University School of Medicine\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Nashville, Tennessee, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Renovatio Clinical - El Paso\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e El Paso, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e NEXT Oncology\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e San Antonio, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e COMPLETED\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Renovatio Clinical\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e The Woodlands, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Virginia Cancer Specialists\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Fairfax, Virginia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Froedtert Hospital and the Medical College of Wisconsin\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Milwaukee, Wisconsin, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06126666\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Seoul National University Bundang Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Seongnam, Seoul, Korea, Republic of\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06126666\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Sevrance Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Seoul, South Korea, Korea, Republic of\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06126666\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Seoul National University Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Seoul, , Korea, Republic of\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06046066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Phase 1 Study of NM6603 in Advanced Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Karmanos Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Detroit, Michigan, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06046066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Phase 1 Study of NM6603 in Advanced Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cleveland Clinic Taussig Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Cleveland, Ohio, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06046066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Phase 1 Study of NM6603 in Advanced Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Tennessee Oncology, PLLC\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Nashville, Tennessee, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06046066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e A Phase 1 Study of NM6603 in Advanced Solid Tumors\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e MD Anderson Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Houston, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04626726\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e No.2 Hospital of Hebei Medical University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Shijiazhuang, Hebei, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e EARLY_PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00930566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Extracorporal Photopheresis Pilot Study\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Centre de Sant\u00e9 - Etablissement Fran\u00e7ais du Sang (EFS)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Lyon, , France\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e ACTIVE_NOT_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00930566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Extracorporal Photopheresis Pilot Study\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e H\u00f4pital Edouard Herriot, Service d'H\u00e9matologie\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Lyon, , France\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05493566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Emory University\u002fWinship Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Atlanta, Georgia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e EARLY_PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06766266\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The First Affiliated Hospital of Chongqing Medica University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e ChongQing, , China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT01613066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Azienda Ospedaliera S Croce e Carle\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Cuneo, , Italy\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05009966\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Beijing Cancer Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Beijing, Beijing, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT03425526\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e M D Anderson Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Houston, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e"],"visible":false,"type":"scattermapbox"},{"hoverinfo":"text","lat":{"dtype":"f8","bdata":"c4Bgjh5DSkAaho+IKa1AQBqGj4gprUBAGoaPiCmtQEAdjxmojF9BQG8qUmFsCUFAjkC8rl8UQUBf7\u002f54rwZBQF\u002fv\u002fnivBkFAX+\u002f+eK8GQUBf7\u002f54rwZBQF\u002fv\u002fnivBkFAG2SSkbO4OUAouFhRg1E6QCBGCI82xjlAIEYIjzbGOUA3T3XIzexEQDdPdcjN7ERAjPhOzHrFREAZyol2Fc5EQGEaho+IwURAvyuC\u002f63QRED2QCswZMlEQMy0\u002fSsrpUNAzLT9KyulQ0Dg88MI4S1FQODzwwjhLUVA7ZklAWqGSUBUjPM3obRGQCHNWDSd2UVArrZif9kRQUBf7\u002f54rwZBQB1aZDvf30BAN091yM3sREDGM2jon9REQOOqsu+KIENA5nRZTGwqRUAlI2dhT3tFQPCiryDNoERArIvbaADDRkDhXS7iOxVCQDXSUnk7wj9AW5TZIJNsPUBVGFsIcig+QE6c3O9QbENAPujZrPqERUBHIF7XL\u002fRHQOTaUDHO30ZA5NpQMc7fRkCe6pCb4cZCQJ7qkJvhxkJADMhe7\u002f5cQkDVsrW+SOBLQC4cCMkCMkZAoGzKFd4dN0BihPBo4zg\u002fQCtNSkG3DzpApvJ2hNN6OEDBxYoaTAdCQAzIXu\u002f+YEFABmSvd3\u002fAQEDEd2LWi1VCQCtNSkG3F0JAYoTwaOM4P0A1JO6x9Ak5QD81XrpJDEJAk8ZoHVWVPkAaFw6EZLlAQPzjvWplFkJA"},"legendgroup":"phase2","lon":{"dtype":"f8","bdata":"ww34\u002fDDSKkAGZK93f\u002fJbwAZkr3d\u002f8lvABmSvd3\u002fyW8Dqz36kiBJXwBqojH+fmV3AQ8U4fxOgXcAdrP9zmI9dwB2s\u002f3OYj13AHaz\u002fc5iPXcAdrP9zmI9dwB2s\u002f3OYj13AoblOIy0RVMDOx7WhYgZUwMai6exkDFTAxqLp7GQMVMDysFBrmulVwPKwUGua6VXAC9KMRdPrVcDB\u002f1ayY+lVwDKs4o3M\u002fVXAwi\u002f186b2VcCAgosVNfJVwAw89x4uJ1PADDz3Hi4nU8AL0oxF08NRwAvSjEXTw1HAQSswZHWFXMC\u002fK4L\u002frexSwMpUwaik2lPATS1b64t+XcAdrP9zmI9dwCLgEKrUGFXA8rBQa5rpVcCA1CZO7uFWwFiQZiyacFXAsHJoke3CVMA4Mo\u002f8wWpVwFmLTwEw\u002fFfAms5OBkerXsAna9RDNLJVwD5cctwpn1rAxJRIopefWMBB1H0AUt9XwG+e6pCbU1PAhzO\u002fmgP6VcA4oRABh7haQKVmD7QCYxNApWYPtAJjE0AM6lvmdF1TwAzqW+Z0XVPAA7LXuz+IU8DmXIqrys5CQBo09E9wMR5AAAAAAABQXEDF5uPaUF1eQKG+ZU6X011AgSGrWz2FXUAPuRluwPVZQPN2hNOCaVxAHsTOFDrJXUCyutVz0j9dQEjhehSuR11Axebj2lBdXkAVb2Qe+a1ZQAZkr3d\u002fmFxAwjQMHxGRXEAipkQSvQRcwNsWZTbIyFzA"},"marker":{"color":{"dtype":"i1","bdata":"CgkJCQkJCQkJCQkJCQkJCQkJCQkJCQkJCQkJCQkJBQUFBQUFBQUFBQUFBQUFBQMAAAcHBwECBgYLCwsLCwsLCwsLCAQE"},"colorscale":[[0.0,"#440154"],[0.1111111111111111,"#482878"],[0.2222222222222222,"#3e4989"],[0.3333333333333333,"#31688e"],[0.4444444444444444,"#26828e"],[0.5555555555555556,"#1f9e89"],[0.6666666666666666,"#35b779"],[0.7777777777777778,"#6ece58"],[0.8888888888888888,"#b5de2b"],[1.0,"#fde725"]],"opacity":0.7,"showscale":false,"size":8},"mode":"markers","name":"Phase 2 Locations","showlegend":false,"text":["\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05821166\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Potential of Moderate Whole Body Hyperthermia to Enhance Response\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Klinik f\u00fcr Radioonkologie und Strahlentherapie\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Berlin, , Germany\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Banner Gateway Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Gilbert, Arizona, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Banner Gateway Medical Pavilion\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Gilbert, Arizona, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Banner MD Anderson Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Gilbert, Arizona, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e University of Arkansas for Medical Sciences - Winthrop P. Rockefeller Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Little Rock, Arkansas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Beverly Hills Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Beverly Hills, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Clinical Research Advisors\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Encino, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Clinical Research Advisors\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaD\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cedars Sinai Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Clinical Research Advisors\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Coral Gables, Florida, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Sylvester Comprehensive Cancer Center- Deerfield Beach\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Deerfield Beach, Florida, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Sylvester Comprehensive Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Miami, Florida, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UHealth Tower\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Miami, Florida, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UChicago Medicine - River East\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Chicago, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e University of Chicago Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Chicago, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UChicago Medicine at Ingalls - Flossmoor\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Flossmoor, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UChicago Medicine Ingalls Memorial\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Harvey, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e University of Chicago Comprehensive Cancer Center at Silver Cross Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e New Lenox, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The University of Chicago Medicine Center for Advanced Care Orland Park\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Orland Park, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UChicago Medicine at Ingalls - Tinley Park\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Tinley Park, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e OIDS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Baltimore, Maryland, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Also Imaging Facility)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Baltimore, Maryland, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Massachusetts General Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Boston, Massachusetts, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Beth Israel Deaconess Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Boston, Massachusetts, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Arthur J.E. Child Comprehensive Cancer Centre\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Calgary, Alberta, Canada\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The Ottawa Hospital - General Campus\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Ottawa, Ontario, Canada\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05090566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Princess Margaret Cancer Centre\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Toronto, Ontario, Canada\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e City of Hope\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Duarte, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Valkyrie Clinical Trials\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Los Angeles, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Winship Cancer Institute - Emory University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Atlanta, Georgia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The University of Chicago Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Chicago, Illinois, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e University of Iowa\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Iowa City, Iowa, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Norton Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Louisville, Kentucky, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Henry Ford Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Detroit, Michigan, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e START Midwest\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Grand Rapids, Michigan, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Nebraska Cancer Specialists\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Omaha, Nebraska, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Providence Portland Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Portland, Oregon, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Vanderbilt University School of Medicine\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Nashville, Tennessee, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Renovatio Clinical - El Paso\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e El Paso, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e NEXT Oncology\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e San Antonio, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e COMPLETED\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Renovatio Clinical\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e The Woodlands, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Virginia Cancer Specialists\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Fairfax, Virginia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04198766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda\u00ae) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Froedtert Hospital and the Medical College of Wisconsin\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Milwaukee, Wisconsin, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT03556566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Open Label Immunotherapy Trial for Ovarian Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Immunitor LLC\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Ulaanbaatar, , Mongolia\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00930566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Extracorporal Photopheresis Pilot Study\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Centre de Sant\u00e9 - Etablissement Fran\u00e7ais du Sang (EFS)\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Lyon, , France\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e ACTIVE_NOT_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00930566\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Extracorporal Photopheresis Pilot Study\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e H\u00f4pital Edouard Herriot, Service d'H\u00e9matologie\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Lyon, , France\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04643366\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Virginia Cancer Institute\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Richmond, Virginia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04643366\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Virginia Commonwealth University Massey Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Richmond, Virginia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04643366\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e VCU Community Memorial Healthcenter\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e South Hill, Virginia, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT00964626\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Russian Academy of Medical Sciences Cancer Research Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Moscow, , Russian Federation\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT01613066\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Azienda Ospedaliera S Croce e Carle\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Cuneo, , Italy\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE1, PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04417166\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Pembrolizumab and Radiotherapy for Patients With NK\u002fT Cell Lymphoma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Sun Yat-sen University Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Guangzhou, , China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04417166\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Pembrolizumab and Radiotherapy for Patients With NK\u002fT Cell Lymphoma\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Shanghai Rui-Jin Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Shanghai, , China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Fujian Cancer Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Fuzhou, Fujian, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The First Affiliated Hospital of Xiamen University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Xiamen, Fujian, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Lanzhou Military Region General Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Lanzhou, Gansu, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e The First Affiliated Hospital of Zhengzhou University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Zhengzhou, Henan, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Huai'an Second People's Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Huaian, Jiangsu, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Qianfoshan Hospital of Shandong Province\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Jinan, Shandong, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Taian City Central Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Taian, Shandong, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Fudan University Shanghai Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Shanghai, Shanghai, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Yunnan Cancer Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Kunming, Yunnan, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06521866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Anyang Cancer Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Anyang, , China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04909866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B\u002fC Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Wuhan Union Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Wuhan, Hubei, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2, PHASE3\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04032626\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e St. Joseph's Hospital and Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Phoenix, Arizona, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e NOT_YET_RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04032626\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cleveland Clinic Lou Ruvo Center for Brain health\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Las Vegas, Nevada, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e"],"visible":false,"type":"scattermapbox"},{"hoverinfo":"text","lat":{"dtype":"f8","bdata":"fGEyVTAGQUAjZ2FPO2RAQFyPwvUo9ENAk8ZoHVWVPkA="},"legendgroup":"phase3","lon":{"dtype":"f8","bdata":"bVZ9rrZQXcCEKjV7oDNYwF2\u002fYDdsGV1AwjQMHxGRXEA="},"marker":{"color":{"dtype":"i1","bdata":"AAEDAg=="},"colorscale":[[0.0,"#440154"],[0.1111111111111111,"#482878"],[0.2222222222222222,"#3e4989"],[0.3333333333333333,"#31688e"],[0.4444444444444444,"#26828e"],[0.5555555555555556,"#1f9e89"],[0.6666666666666666,"#35b779"],[0.7777777777777778,"#6ece58"],[0.8888888888888888,"#b5de2b"],[1.0,"#fde725"]],"opacity":0.7,"showscale":false,"size":8},"mode":"markers","name":"Phase 3 Locations","showlegend":false,"text":["\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT03598426\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Loma Linda University Cancer Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Loma Linda, California, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE3\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT03769766\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e UT Southwestern Medical Center\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Dallas, Texas, United States\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE3\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT05074966\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC Pts\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Cancer Hospital & Institute, Chinese Academy of Medical Sciences\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Beijing, , China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE3\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT04909866\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B\u002fC Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Wuhan Union Hospital\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Wuhan, Hubei, China\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE2, PHASE3\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e"],"visible":false,"type":"scattermapbox"},{"hoverinfo":"text","lat":{"dtype":"f8","bdata":"nL8JhQgQPkAxX16Afbw+QIfcDDfgL0pA"},"legendgroup":"phase4","lon":{"dtype":"f8","bdata":"1cqEX+o\u002fP0CmCkYldTJTQB5QNuUKjxNA"},"marker":{"color":{"dtype":"i1","bdata":"AgAB"},"colorscale":[[0.0,"#440154"],[0.1111111111111111,"#482878"],[0.2222222222222222,"#3e4989"],[0.3333333333333333,"#31688e"],[0.4444444444444444,"#26828e"],[0.5555555555555556,"#1f9e89"],[0.6666666666666666,"#35b779"],[0.7777777777777778,"#6ece58"],[0.8888888888888888,"#b5de2b"],[1.0,"#fde725"]],"opacity":0.7,"showscale":false,"size":8},"mode":"markers","name":"Phase 4 Locations","showlegend":false,"text":["\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT06777966\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Nebulized Versus Intravenous Tranexamic Acid on Surgical Field Quality in Patients Undergoing Endoscopic Sinus Surgeries\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Faculty of Medicine, Cairo University\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Cairo, , Egypt\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE4\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT01901666\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e Postgraduate Institute of Medical Education and Research\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Chandigarh, UT, India\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE4\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e","\u003cb\u003eNCT ID:\u003c\u002fb\u003e NCT03646266\u003cbr\u003e\u003cb\u003eTitle:\u003c\u002fb\u003e Partial Neuromuscular Blockade for Lung Protective Mechanical Ventilation\u003cbr\u003e\u003cb\u003eFacility:\u003c\u002fb\u003e VUmc\u003cbr\u003e\u003cb\u003eLocation:\u003c\u002fb\u003e Amsterdam, , Netherlands\u003cbr\u003e\u003cb\u003ePhase:\u003c\u002fb\u003e PHASE4\u003cbr\u003e\u003cb\u003eStatus:\u003c\u002fb\u003e RECRUITING\u003cbr\u003e"],"visible":false,"type":"scattermapbox"}],                        {"template":{"data":{"histogram2dcontour":[{"type":"histogram2dcontour","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"choropleth":[{"type":"choropleth","colorbar":{"outlinewidth":0,"ticks":""}}],"histogram2d":[{"type":"histogram2d","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"heatmap":[{"type":"heatmap","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"contourcarpet":[{"type":"contourcarpet","colorbar":{"outlinewidth":0,"ticks":""}}],"contour":[{"type":"contour","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"surface":[{"type":"surface","colorbar":{"outlinewidth":0,"ticks":""},"colorscale":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]]}],"mesh3d":[{"type":"mesh3d","colorbar":{"outlinewidth":0,"ticks":""}}],"scatter":[{"fillpattern":{"fillmode":"overlay","size":10,"solidity":0.2},"type":"scatter"}],"parcoords":[{"type":"parcoords","line":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatterpolargl":[{"type":"scatterpolargl","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"bar":[{"error_x":{"color":"#2a3f5f"},"error_y":{"color":"#2a3f5f"},"marker":{"line":{"color":"#E5ECF6","width":0.5},"pattern":{"fillmode":"overlay","size":10,"solidity":0.2}},"type":"bar"}],"scattergeo":[{"type":"scattergeo","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatterpolar":[{"type":"scatterpolar","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"histogram":[{"marker":{"pattern":{"fillmode":"overlay","size":10,"solidity":0.2}},"type":"histogram"}],"scattergl":[{"type":"scattergl","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatter3d":[{"type":"scatter3d","line":{"colorbar":{"outlinewidth":0,"ticks":""}},"marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scattermap":[{"type":"scattermap","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scattermapbox":[{"type":"scattermapbox","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scatterternary":[{"type":"scatterternary","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"scattercarpet":[{"type":"scattercarpet","marker":{"colorbar":{"outlinewidth":0,"ticks":""}}}],"carpet":[{"aaxis":{"endlinecolor":"#2a3f5f","gridcolor":"white","linecolor":"white","minorgridcolor":"white","startlinecolor":"#2a3f5f"},"baxis":{"endlinecolor":"#2a3f5f","gridcolor":"white","linecolor":"white","minorgridcolor":"white","startlinecolor":"#2a3f5f"},"type":"carpet"}],"table":[{"cells":{"fill":{"color":"#EBF0F8"},"line":{"color":"white"}},"header":{"fill":{"color":"#C8D4E3"},"line":{"color":"white"}},"type":"table"}],"barpolar":[{"marker":{"line":{"color":"#E5ECF6","width":0.5},"pattern":{"fillmode":"overlay","size":10,"solidity":0.2}},"type":"barpolar"}],"pie":[{"automargin":true,"type":"pie"}]},"layout":{"autotypenumbers":"strict","colorway":["#636efa","#EF553B","#00cc96","#ab63fa","#FFA15A","#19d3f3","#FF6692","#B6E880","#FF97FF","#FECB52"],"font":{"color":"#2a3f5f"},"hovermode":"closest","hoverlabel":{"align":"left"},"paper_bgcolor":"white","plot_bgcolor":"#E5ECF6","polar":{"bgcolor":"#E5ECF6","angularaxis":{"gridcolor":"white","linecolor":"white","ticks":""},"radialaxis":{"gridcolor":"white","linecolor":"white","ticks":""}},"ternary":{"bgcolor":"#E5ECF6","aaxis":{"gridcolor":"white","linecolor":"white","ticks":""},"baxis":{"gridcolor":"white","linecolor":"white","ticks":""},"caxis":{"gridcolor":"white","linecolor":"white","ticks":""}},"coloraxis":{"colorbar":{"outlinewidth":0,"ticks":""}},"colorscale":{"sequential":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]],"sequentialminus":[[0.0,"#0d0887"],[0.1111111111111111,"#46039f"],[0.2222222222222222,"#7201a8"],[0.3333333333333333,"#9c179e"],[0.4444444444444444,"#bd3786"],[0.5555555555555556,"#d8576b"],[0.6666666666666666,"#ed7953"],[0.7777777777777778,"#fb9f3a"],[0.8888888888888888,"#fdca26"],[1.0,"#f0f921"]],"diverging":[[0,"#8e0152"],[0.1,"#c51b7d"],[0.2,"#de77ae"],[0.3,"#f1b6da"],[0.4,"#fde0ef"],[0.5,"#f7f7f7"],[0.6,"#e6f5d0"],[0.7,"#b8e186"],[0.8,"#7fbc41"],[0.9,"#4d9221"],[1,"#276419"]]},"xaxis":{"gridcolor":"white","linecolor":"white","ticks":"","title":{"standoff":15},"zerolinecolor":"white","automargin":true,"zerolinewidth":2},"yaxis":{"gridcolor":"white","linecolor":"white","ticks":"","title":{"standoff":15},"zerolinecolor":"white","automargin":true,"zerolinewidth":2},"scene":{"xaxis":{"backgroundcolor":"#E5ECF6","gridcolor":"white","linecolor":"white","showbackground":true,"ticks":"","zerolinecolor":"white","gridwidth":2},"yaxis":{"backgroundcolor":"#E5ECF6","gridcolor":"white","linecolor":"white","showbackground":true,"ticks":"","zerolinecolor":"white","gridwidth":2},"zaxis":{"backgroundcolor":"#E5ECF6","gridcolor":"white","linecolor":"white","showbackground":true,"ticks":"","zerolinecolor":"white","gridwidth":2}},"shapedefaults":{"line":{"color":"#2a3f5f"}},"annotationdefaults":{"arrowcolor":"#2a3f5f","arrowhead":0,"arrowwidth":1},"geo":{"bgcolor":"white","landcolor":"#E5ECF6","subunitcolor":"white","showland":true,"showlakes":true,"lakecolor":"white"},"title":{"x":0.05},"mapbox":{"style":"light"}}},"mapbox":{"center":{"lat":40.19097656934307,"lon":-21.0722699270073},"style":"open-street-map","zoom":1},"margin":{"r":0,"t":50,"l":0,"b":10},"height":800,"annotations":[{"align":"center","font":{"size":16},"showarrow":false,"text":"Example: Cancer Clinical Trials Map","x":0.5,"xref":"paper","y":1.05,"yref":"paper"},{"align":"left","bgcolor":"rgba(255, 255, 255, 0.8)","borderpad":4,"font":{"size":14},"showarrow":false,"text":"\u003cb\u003eFilter Options\u003c\u002fb\u003e","x":1.0,"xref":"paper","y":0.95,"yref":"paper"},{"align":"left","bgcolor":"rgba(255, 255, 255, 0.8)","borderpad":4,"font":{"size":12},"showarrow":false,"text":"\u003cb\u003eStatistics\u003c\u002fb\u003e\u003cbr\u003eTotal Trials: 50\u003cbr\u003eTotal Locations: 137\u003cbr\u003eCountries: 17\u003cbr\u003ePhase 1 Trials: 10\u003cbr\u003ePhase 2 Trials: 12\u003cbr\u003ePhase 3 Trials: 4\u003cbr\u003ePhase 4 Trials: 3","x":1.0,"xref":"paper","y":0.35,"yref":"paper"}],"updatemenus":[{"bgcolor":"rgba(255, 255, 255, 0.8)","bordercolor":"rgba(0, 0, 0, 0.4)","buttons":[{"args":[{"visible":[true,false,false,false,false]}],"label":"All Phases","method":"update"},{"args":[{"visible":[false,true,false,false,false]}],"label":"Phase 1 (10 trials)","method":"update"},{"args":[{"visible":[false,false,true,false,false]}],"label":"Phase 2 (12 trials)","method":"update"},{"args":[{"visible":[false,false,false,true,false]}],"label":"Phase 3 (4 trials)","method":"update"},{"args":[{"visible":[false,false,false,false,true]}],"label":"Phase 4 (3 trials)","method":"update"}],"direction":"down","font":{"size":12},"showactive":true,"x":1.0,"xanchor":"right","y":0.85,"yanchor":"top"}]},                        {"responsive": true}                    )                };            </script>        </div>
</body>
</html>